30 Years of Progress: Mobilizing the Health Sector to End Violence Against Women and Girls In the three decades since the landmark Beijing Platform for Action on Women was adopted…
BioMarin Bolsters Enzyme Therapy Portfolio with $270 Million Acquisition of Rare Disease Specialist Inozyme Pharma BioMarin Pharmaceutical, a leading biotech company focused on rare diseases and enzyme replacement therapies, announced…
Incyte’s Zynyz Secures First-Line Approval in Anal Cancer, Marking a Milestone for PD-1 Therapy in Rare Tumor Type In a significant development for the treatment of a rare and underserved…
Global Youth Scientists Shine at 75th Regeneron ISEF, Sharing Over $9 Million in Prizes In a celebration of youthful brilliance, scientific curiosity, and international collaboration, the 75th Annual Regeneron International…
European Commission Grants Approval to Bristol Myers Squibb’s Perioperative Opdivo Regimen for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% Bristol Myers Squibb has announced that the European Commission (EC) has…
Merck to Present Robust Set of Pulmonary Arterial Hypertension Data at ATS 2025, Underscoring Long-Term Commitment to Innovation and Patient Outcomes Merck , known as MSD outside the United States…
Leadership Transition at Novo Nordisk: CEO Lars Fruergaard Jørgensen to Step Down Amid Market Headwinds and Strategic Realignment In a significant leadership transition, Novo Nordisk A/S announced that Lars Fruergaard…
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr), the First and Only Approved First-Line Treatment for Advanced Anal Cancer in the U.S. Incyte Corporation (Nasdaq: INCY), a global biopharmaceutical company focused…
Merck Delivers Resilient Growth Across All Divisions in Q1 2025, Advances Strategic Expansion with SpringWorks Acquisition Merck, the global science and technology powerhouse, began 2025 on strong footing, demonstrating solid…
Regeneron Triumphs in Landmark Antitrust Case Against Amgen Over PCSK9 Inhibitor Market Practices In a major legal victory that could have lasting implications for the biotechnology and pharmaceutical industries, Regeneron…
CSL Behring’s Broadmeadows Plasma Facility Wins Prestigious 2025 ISPE Facility of the Year Award for Pharma 4.0 Innovation CSL Behring has earned global recognition for its trailblazing approach to pharmaceutical…
Gilead and Kite Set to Showcase Transformative Oncology Data at 2025 ASCO and EHA Conferences, Highlighting Advances in Breast Cancer, Multiple Myeloma, and Glioblastoma Gilead Sciences,and its Kite subsidiary are…